Skip to content

Oruka Therapeutics, Inc. ORKA Change in Lease Liabilities

Change in Lease Liabilities at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$547K-260%
Alumis Inc. logo
Alumis Inc.ALMS
-$1.25M-102%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$802K+20.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s change in lease liabilities?
Oruka Therapeutics, Inc. (ORKA) reported change in lease liabilities of -$125K in Q1 2026.
How has Oruka Therapeutics, Inc.'s change in lease liabilities changed year-over-year?
Oruka Therapeutics, Inc.'s change in lease liabilities decreased by 495.2% year-over-year, from -$21K to -$125K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.